assessing the role of miasm in choosing the correct remedy for the management of cases of generalized anxiety disorder
Phase 3
- Conditions
- Health Condition 1: F411- Generalized anxiety disorder
- Registration Number
- CTRI/2021/08/035796
- Lead Sponsor
- nil
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.newly diagnosed generalized anxiety disorder
2.patient opting for homoeopathic treatment for chronic illness
3.patient complying for regular follow up
4.patient who have written the consent form
5.patient of both sexes
Exclusion Criteria
1.patients undertaking any other treatment along with homoeopathic mode of treatment
2.patient who have not written the consent form
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement in generalized anxiety disorder 7 scale before and after the interventionTimepoint: At baseline, 2 weeks or 4 weeks or 8 weeks or 12 weeks depending on case
- Secondary Outcome Measures
Name Time Method improvement in quality of life before and after the treatmentTimepoint: At baseline, 2 weeks or 4 weeks or 8 weeks or 12 weeks depending on case